An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Nurtec ODT

Chemical Namerimegepant
Dosage FormTablet (oral; 75 mg)
Drug ClassReceptor antagonists
SystemNervous
CompanyBiohaven Pharmaceuticals, Inc.
Approval Year2020

Indication

  • Indicated for the acute treatment of migraine with or without aura in adults.
Last updated on 12/7/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nurtec ODT (rimegepant) Prescribing Information.2020Biohaven Pharmaceuticals, Inc. New Haven, CT
Document TitleYearSource
Novel therapies in acute migraine management: Small-molecule calcitonin gene-receptor antagonists and serotonin 1F receptor agonist.2020Annals of Pharmacotherapy
Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials.2020Frontiers in Pharmacology